The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IBC 2024 | AI-REAL: improving diagnosis and treatment in EBV-associated Burkitt lymphoma
In this video, Anna Schuh, MD, PhD, FRCP, FRCPath, University of Oxford, Oxford, UK, gives an overview of the AI-REAL program, which is an ongoing study that aims to improve diagnosis and treatment in children with EBV-associated Burkitt lymphoma in Sub-Saharan Africa. Prof. Schuh also highlights ongoing research into a vaccine against EBV, which could play a crucial role in preventing post-treatment relapse in these children. This session was filmed at IBC 2024, held in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
